SLC16A13: A Potential Drug Target for Synaptophysin and Brain Function
SLC16A13: A Potential Drug Target for Synaptophysin and Brain Function
SLC16A13 is a protein that is expressed in various tissues throughout the body. It is a member of the SLC16A family, which is known for its role in the transport of various molecules across cell membranes. SLC16A13 is specifically expressed in the brain, where it is involved in the transport of a protein called synaptophysin.
Synaptophysin is a protein that is involved in the structure and function of the synapses, which are the chemical and electrical barriers that separate neurons from each other. It is also involved in the transport of other molecules across cell membranes, including neurotransmitters such as dopamine and GABA.
SLC16A13 is thought to be a drug target because it is involved in the transport of synaptophysin, which is a protein that has been shown to play a role in various neurological disorders, including Alzheimer's disease and Parkinson's disease. Studies have shown that individuals with certain genetic mutations, such as those in the SLC16A family, are at an increased risk of developing these disorders.
In addition to its involvement in the transport of synaptophysin, SLC16A13 is also thought to be involved in the regulation of various signaling pathways that are involved in brain function. For example, SLC16A13 has been shown to be involved in the regulation of the activity of a protein called TrkB, which is involved in the production of neurotransmitters such as dopamine and GABA.
SLC16A13 is also thought to be involved in the regulation of the activity of other proteins that are involved in brain function, such as the protein called Egr1. Egr1 is a transcription factor that is involved in the regulation of various genes that are involved in brain development and function.
SLC16A13 is also thought to be involved in the regulation of the activity of a protein called Hax, which is involved in the production of the neurotransmitter acetylcholine.
In conclusion, SLC16A13 is a protein that is involved in the transport of synaptophysin across cell membranes. It is also thought to be involved in the regulation of various signaling pathways that are involved in brain function, and is therefore thought to be a potential drug target. Further research is needed to determine the exact role of SLC16A13 in brain function and the potential benefits of targeting this protein.
Protein Name: Solute Carrier Family 16 Member 13
Functions: Proton-linked monocarboxylate transporter. May catalyze the transport of monocarboxylates across the plasma membrane
More Common Targets
SLC16A14 | SLC16A2 | SLC16A3 | SLC16A4 | SLC16A5 | SLC16A6 | SLC16A6P1 | SLC16A7 | SLC16A8 | SLC16A9 | SLC17A1 | SLC17A2 | SLC17A3 | SLC17A4 | SLC17A5 | SLC17A6 | SLC17A7 | SLC17A8 | SLC17A9 | SLC18A1 | SLC18A2 | SLC18A3 | SLC18B1 | SLC19A1 | SLC19A2 | SLC19A3 | SLC1A1 | SLC1A2 | SLC1A3 | SLC1A4 | SLC1A5 | SLC1A6 | SLC1A7 | SLC20A1 | SLC20A1-DT | SLC20A2 | SLC22A1 | SLC22A10 | SLC22A11 | SLC22A12 | SLC22A13 | SLC22A14 | SLC22A15 | SLC22A16 | SLC22A17 | SLC22A18 | SLC22A18AS | SLC22A2 | SLC22A20P | SLC22A23 | SLC22A24 | SLC22A25 | SLC22A3 | SLC22A31 | SLC22A4 | SLC22A5 | SLC22A6 | SLC22A7 | SLC22A8 | SLC22A9 | SLC23A1 | SLC23A2 | SLC23A3 | SLC24A1 | SLC24A2 | SLC24A3 | SLC24A3-AS1 | SLC24A4 | SLC24A5 | SLC25A1 | SLC25A10 | SLC25A11 | SLC25A12 | SLC25A13 | SLC25A14 | SLC25A15 | SLC25A16 | SLC25A17 | SLC25A18 | SLC25A19 | SLC25A2 | SLC25A20 | SLC25A21 | SLC25A21-AS1 | SLC25A22 | SLC25A23 | SLC25A24 | SLC25A24P1 | SLC25A25 | SLC25A25-AS1 | SLC25A26 | SLC25A27 | SLC25A28 | SLC25A29 | SLC25A3 | SLC25A30 | SLC25A31 | SLC25A32 | SLC25A33 | SLC25A34